Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Deerfield Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Deerfield Management

Deerfield Management

Operating

NY-based Deerfield Management, a leading global investment firm specializing in healthcare and biotech sectors.

Location
New York City, NY, US
Founded
1994
Firm
Compare
Portfolio
Fundraising
Employees
Website

Investments

Cohere Health
Cohere Health

Total Raised

$96.1M

Rounds

3

Series C$50MFebruary 2024
Bicara Therapeutics
Bicara Therapeutics

Total Raised

$313M

Rounds

3

Series C$165MDecember 2023
Adela
Adela

Total Raised

$108M

Rounds

2

Series A$48MSeptember 2023
Actio Biosciences
Actio Biosciences

Total Raised

$55M

Rounds

1

Series A$55MSeptember 2023
Octave Bioscience
Octave Bioscience

Total Raised

$91M

Rounds

6

Series B$32.5MJuly 2023
Presidio Medical
Presidio Medical

Total Raised

$102M

Rounds

3

Series C$72MJune 2023
Bitterroot Bio
Bitterroot Bio

Total Raised

$145M

Rounds

1

Series A$145MJune 2023
Cortica
Cortica
Series D

Total Raised

$175M

Rounds

7

Series D$75MApril 2023
Perceive Biotherapeutics
Perceive Biotherapeutics

Total Raised

$78M

Rounds

1

Series B$78MJanuary 2023
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series D$178MNovember 2022
Abeona Therapeutics
Abeona Therapeutics
Public

Total Raised

$354.7M

Rounds

13

Post Ipo Equity$35MNovember 2022
Intus Care
Intus Care

Total Raised

$32.5M

Rounds

9

Series A$14.1MNovember 2022
Cota Healthcare
Cota Healthcare

Total Raised

$109M

Rounds

7

Series EOctober 2022
Sientra
Sientra
Public

Total Raised

$334.7M

Rounds

8

Post Ipo DebtOctober 2022
Pleno
Pleno

Total Raised

$55M

Rounds

2

Series A$40MOctober 2022
Innervace
Innervace

Total Raised

$40M

Rounds

1

Series A$40MSeptember 2022
SpringWorks Therapeutics
SpringWorks Therapeutics
Public

Total Raised

$1B

Rounds

6

Post Ipo Equity$225MSeptember 2022
Insilico Medicine
Insilico Medicine

Total Raised

$401.3M

Rounds

11

Series D$35MAugust 2022
Series D$60MJune 2022
Vicinitas Therapeutics
Vicinitas Therapeutics

Total Raised

$65M

Rounds

1

Series A$65MJuly 2022
Humanity Health
Humanity Health

Total Raised

$6M

Rounds

1

Series A$6MJuly 2022
Epic Sciences
Epic Sciences

Total Raised

$219.5M

Rounds

8

Series F$43MJune 2022
UTR Therapeutics
UTR Therapeutics

Total Raised

$400k

Rounds

1

Pre-Seed$400kMay 2022
Acutus Medical
Acutus Medical
Acquired

Total Raised

$343.2M

Rounds

10

Post Ipo Debt$35MApril 2022
Apertura Gene Therapy
Apertura Gene Therapy

Total Raised

$67M

Rounds

1

Series A$67MApril 2022